Re: Health Challenges and Spirituality & follow ups on new trials.

[Guest guest]

Lottie--

You've done it again! mORE FANTASTIC information and I can't

imagine where you find it all! Just wonderful. By the way, my

family LOVED your gumbo recipe and we ate the entire batch and

practically licked the pot! It was just wonderful. They are

already nagging me to make it again. The only thing I was wondering

about was the sausage--what kind do you recommend? I found the

spiciest Italian sausage I could because that is all there was, but

if you have a better suggestion, I would love to know what you use.

Hugs and love,

Vicki

>

> How health challenges can change you spiritually. Seeing through

someone else's eyes. Interesting article.

>

http://cms.carepages.com/CarePages/en/Newsletters/7_08/spirituality_h

elps.html?ipc=nlaug_spotlight_1

>

> www.familydoctor.org offers information on how spirituality is

related to your

health.http://familydoctor.org/online/famdocen/home/articles/650.html

>

> (Reuters) - Novartis cancer drug Glivec failed to meet its main

target in a late-stage study of patients with chronic myeloid

leukaemia (CML), according to the Swiss drugmaker.

> http://www.reuters.com/article/rbssPharmaceuticals%20-%

20Diversified/idUSL1351443720080613

>

> Novartis Clinical trial search

>

http://www.novartisclinicaltrials.com/webapp/etrials/DiseaseID30/Chro

nic-Myelogenous-Leukemia-(CML)-clinical-trials.go?

pl_id=bmretk110000 & gclid=CKCn0rmw6JQCFReenAodIim-SQ

>

> OHSU Cancer Institute Researchers Find New Drug Candidate Knocks

Out Resistant Form Of Chronic Myeloid Leukemia. The combination of

SGX393 with either Sprycel or Tasigna completely suppressed

resistant growth.

> http://www.ohsu.edu/ohsuedu/newspub/releases/121007drug.cfm

>

> AP24534 has been shown to selectively block a series of well-

validated cancer targets known to play critical roles in the

pathogenesis of several hematological cancers and solid tumors.

Especially in patients with the drug-resistant forms of CML, where

the genetic basis for the disease can be readily measured in

individual patients, we expect this trial to provide insights into

the potential therapeutic effects of AP24534 early in its clinical

development. "

>

https://www.sharebuilder.com/sharebuilder/Research/MarketUpdate/Stock

News.aspx?GUID={C080AB54-2535-4A1D-A868-69BA2FFAA4D8} & Symbol=ARIA

>

> Blessings,

> Lottie

>

>

>

>

>